Antibody data
- Antibody Data
- Antigen structure
- References [7]
- Comments [0]
- Validations
- Blocking/Neutralizing [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- AF633 - Provider product page
- Provider
- Novus Biologicals
- Product name
- Goat Polyclonal TRAILR4/TNFRSF10D/DcR2 Antibody
- Antibody type
- Polyclonal
- Description
- Immunogen affinity purified. Detects human TRAIL R4/TNFRSF10D in direct ELISAs and Western blots. In Western blots, less than 5% cross-reactivity with recombinant human (rh) TRAIL R1, rhTRAIL R2, and rhTRAIL R3 is observed.
- Reactivity
- Human
- Host
- Goat
- Isotype
- IgG
- Vial size
- 100 ug
- Concentration
- LYOPH
- Storage
- Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 degreesC as supplied. 1 month, 2 to 8 degreesC under sterile conditions after reconstitution. 6 months, -20 to -70 degreesC under sterile conditions after reconstitution.
Submitted references Dual role of DR5 in death and survival signaling leads to TRAIL resistance in cancer cells.
Tumor necrosis factor-related apoptosis-inducing ligand promotes migration of human bone marrow multipotent stromal cells.
Differential response of p53 and p21 on HDAC inhibitor-mediated apoptosis in HCT116 colon cancer cells in vitro and in vivo.
Acquired resistance to TRAIL-induced apoptosis in human ovarian cancer cells is conferred by increased turnover of mature caspase-3.
Death receptors, Fas and TRAIL receptors, are involved in human osteoclast apoptosis.
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) induces rheumatoid arthritis synovial fibroblast proliferation through mitogen-activated protein kinases and phosphatidylinositol 3-kinase/Akt.
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) sequentially upregulates nitric oxide and prostanoid production in primary human endothelial cells.
Shlyakhtina Y, Pavet V, Gronemeyer H
Cell death & disease 2017 Aug 31;8(8):e3025
Cell death & disease 2017 Aug 31;8(8):e3025
Tumor necrosis factor-related apoptosis-inducing ligand promotes migration of human bone marrow multipotent stromal cells.
Secchiero P, Melloni E, Corallini F, Beltrami AP, Alviano F, Milani D, D'Aurizio F, di Iasio MG, Cesselli D, Bagnara GP, Zauli G
Stem cells (Dayton, Ohio) 2008 Nov;26(11):2955-63
Stem cells (Dayton, Ohio) 2008 Nov;26(11):2955-63
Differential response of p53 and p21 on HDAC inhibitor-mediated apoptosis in HCT116 colon cancer cells in vitro and in vivo.
Zopf S, Neureiter D, Bouralexis S, Abt T, Glaser KB, Okamoto K, Ganslmayer M, Hahn EG, Herold C, Ocker M
International journal of oncology 2007 Dec;31(6):1391-402
International journal of oncology 2007 Dec;31(6):1391-402
Acquired resistance to TRAIL-induced apoptosis in human ovarian cancer cells is conferred by increased turnover of mature caspase-3.
Lane D, Côté M, Grondin R, Couture MC, Piché A
Molecular cancer therapeutics 2006 Mar;5(3):509-21
Molecular cancer therapeutics 2006 Mar;5(3):509-21
Death receptors, Fas and TRAIL receptors, are involved in human osteoclast apoptosis.
Roux S, Lambert-Comeau P, Saint-Pierre C, Lépine M, Sawan B, Parent JL
Biochemical and biophysical research communications 2005 Jul 22;333(1):42-50
Biochemical and biophysical research communications 2005 Jul 22;333(1):42-50
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) induces rheumatoid arthritis synovial fibroblast proliferation through mitogen-activated protein kinases and phosphatidylinositol 3-kinase/Akt.
Morel J, Audo R, Hahne M, Combe B
The Journal of biological chemistry 2005 Apr 22;280(16):15709-18
The Journal of biological chemistry 2005 Apr 22;280(16):15709-18
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) sequentially upregulates nitric oxide and prostanoid production in primary human endothelial cells.
Zauli G, Pandolfi A, Gonelli A, Di Pietro R, Guarnieri S, Ciabattoni G, Rana R, Vitale M, Secchiero P
Circulation research 2003 Apr 18;92(7):732-40
Circulation research 2003 Apr 18;92(7):732-40
No comments: Submit comment
Supportive validation
- Submitted by
- Novus Biologicals (provider)
- Main image
- Experimental details
- TRAIL R4/TNFRSF10D Inhibition of TRAIL/TNFSF10-induced Cytotoxicity and Neutralization by Human TRAIL R4/TNFRSF10D Antibody. In the presence of a cross-linking antibody, Mouse polyHistidine Monoclonal Antibody (5 µg/mL, Catalog # MAB050) and the metabolic inhibitor actinomycin D (1 µg/mL), Recombinant Human TRAIL R4/TNFRSF10D Fc Chimera (Catalog # 633-TR) inhibits Recombinant Human TRAIL/TNFSF10 (Catalog # 375-TL) induced cytotoxicity in the L-929 mouse fibroblast cell line in a dose-dependent manner (orange line), as measured by crystal violet staining. Under these conditions, inhibition of Recombinant Human TRAIL/TNFSF10 (12 ng/mL) activity elicited by Recombinant Human TRAIL R4/TNFRSF10D Fc Chimera (10 ng/mL) is neutralized (green line) by increasing concentrations of Goat Anti-Human TRAIL R4/ TNFRSF10D Antigen Affinity-purified Polyclonal Antibody (Catalog # AF633). The ND50 is typically 0.03-0.1 µg/mL.